(19)

(11)

EP 4 548 098 A2

(12)

(88) Date of publication A3: 02.05.2024 (43) Date of publication: 07.05.2025 Bulletin 2025/19 (21) Application number: 23847532.1 (22) Date of filing: 26.07.2023

(51) International Patent Classification (IPC):  G01N 33/53(2006.01) A61K 39/215(2006.01) A61K 38/16(2006.01) G01N 33/50(2006.01) (52) Cooperative Patent Classification (CPC): C12N 2770/20022; C07K 14/005 (86) International application number: PCT/US2023/071044 (87) International publication number: WO 2024/026360 (01.02.2024 Gazette 2024/05)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 26.07.2022 US 202263392390 P 12.09.2022 US 202263405653 P 30.11.2022 US 202263428991 P (71) Applicant: Novavax, Inc. Gaithersburg, MD 20878 (US)	(72) Inventors: PLESTED, Joyce S. Gaithersburg, Maryland 20878 (US) KALKERI, Raj Gaithersburg, Maryland 20878 (US) (74) Representative: Danner, Stefan  Danner BioPharm IP Ludwigstraße 8 80539 München 80539 München (DE)